Epigenetic changes in renal genes dysregulated in mouse and rat models of type 1 diabetes.

作者: Radko Komers , Daniel Mar , Oleg Denisenko , Bei Xu , Terry T Oyama

DOI: 10.1038/LABINVEST.2013.47

关键词: EZH2BiologyGeneMolecular biologyMethyltransferaseHistone H3ChromatinEpigeneticsDemethylaseGene silencing

摘要: Epigenetic processes are increasingly being recognized as factors in the pathophysiology of diabetes complications, but few chromatin studies have been done diabetic nephropathy (DN). We hypothesized that changes mRNA expression DN-related genes associated with epigenetic alterations and aberrant histone-modifying enzymes. RT-PCR a matrix–chromatin immunoprecipitation platform were used to examine renal expression, RNA polymerase II (Pol II) recruitment, marks at mouse (OVE26) streptozotocin-induced rat models type 1 diabetes. Diabetes induced Cox2, S100A4/FSP-1, vimentin both DN. Mcp-1 laminin γ1 (Lamc1) increased mice not rats. Comparison Pol levels suggested diabetes-induced these transcripts is mediated by transcriptional posttranscriptional processes. Decreases histone H3 lysine 27 tri-methylation (H3K27m3, silencing mark) increases 4 di-methylation (H3K4m2, activating most consistent tested genes. In agreement results, immunoblot analysis showed protein abundance H3K27m2/3 demethylase KDM6A, no cognate methyltransferase Ezh2 kidneys OVE26 compared controls. rats, was higher without demonstrating mechanisms DN-induced H3K27m3 loss could be species specific. summary, we show altered some recruitment corresponding decrease repressive selected loci, least equivalent This pattern contribute diabetes-mediated transitions facilitate kidney.

参考文章(51)
Feng Miao, Xiwei Wu, Lingxiao Zhang, Arthur D. Riggs, Rama Natarajan, Histone methylation patterns are cell-type specific in human monocytes and lymphocytes and well maintained at core genes. Journal of Immunology. ,vol. 180, pp. 2264- 2269 ,(2008) , 10.4049/JIMMUNOL.180.4.2264
Louisa M Villeneuve, Marpadga A Reddy, Rama Natarajan, Epigenetics: deciphering its role in diabetes and its chronic complications Clinical and Experimental Pharmacology and Physiology. ,vol. 38, pp. 451- 459 ,(2011) , 10.1111/J.1440-1681.2011.05497.X
Suman Setty, Alfred A Michael, Alfred J Fish, S Michael Mauer, Ralph J Butkowski, Ismo Virtanen, Youngki Kim, Differential expression of laminin isoforms in diabetic nephropathy and other renal diseases Modern Pathology. ,vol. 25, pp. 859- 868 ,(2012) , 10.1038/MODPATHOL.2011.216
H.B. Lee, H. Noh, J.Y. Seo, M.R. Yu, H. Ha, Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy. Kidney International. ,vol. 72, ,(2007) , 10.1038/SJ.KI.5002388
Yi Liu, Renaud Dentin, Danica Chen, Susan Hedrick, Kim Ravnskjaer, Simon Schenk, Jill Milne, David J. Meyers, Phil Cole, John Yates III, Jerrold Olefsky, Leonard Guarente, Marc Montminy, A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange Nature. ,vol. 456, pp. 269- 273 ,(2008) , 10.1038/NATURE07349
Tomek Swigut, Joanna Wysocka, H3K27 Demethylases, at Long Last Cell. ,vol. 131, pp. 29- 32 ,(2007) , 10.1016/J.CELL.2007.09.026
Michele Rossini, Boonyarit Cheunsuchon, Ellen Donnert, Li-Jun Ma, James W. Thomas, Eric G. Neilson, Agnes B. Fogo, Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease Kidney International. ,vol. 68, pp. 2621- 2628 ,(2005) , 10.1111/J.1523-1755.2005.00734.X
C. David Allis, Shelley L. Berger, Jacques Cote, Sharon Dent, Thomas Jenuwien, Tony Kouzarides, Lorraine Pillus, Danny Reinberg, Yang Shi, Ramin Shiekhattar, Ali Shilatifard, Jerry Workman, Yi Zhang, New nomenclature for chromatin-modifying enzymes. Cell. ,vol. 131, pp. 633- 636 ,(2007) , 10.1016/J.CELL.2007.10.039